medigraphic.com
ISSN 1608-8921 (Print)

2013, Number 2

<< Back Next >>

Gaceta Médica Espirituana 2013; 15 (2)

Syndrome of Lynch type II. Case presentation

Castellón MS, Peraza GH, Pompa OO

Language: Spanish
References: 13
Page:
PDF size: 232.79 Kb.


ABSTRACT

Background: hereditary colorectal cancer non-related to polyposis associated to extraintestinal neoplasias is called syndrome of Lynch type II and its diagnosis constitutes a challenge for medical staff. Objective: to make possible through a case presentation the clinical thought and the scientific up-dating in this entity to make a more accurate diagnosis. Case presentation: a forty –nine years old patient was admitted for a palpable mass on the left iliac fossa and hypogastrium. A surgical reception was carried out and a papillary mucinous cystadenocarcinoma of ovary was diagnosed for which chemotherapy was prescribed. Two years she was admitted for lower hemoabdomen pain, asthenia, dizziness and cutaneous mucosa paleness. After another surgery a sigmoid colon adenocarcinoma was diagnosed. Later the patient died due to a bleeding and multiorgan failure. Conclusions: based on the criteria of Amsterdam and Bethesda a diagnosis was made of a syndrome of Lynch type II. Due to the frequency of the non-polyposic hereditary variant of the colorectal cancers it is mandatory an integral evaluation of the patient and a coherent clinical judgment in order to improve the diagnostic certainty in a syndrome which is not infrequent but poorly diagnosed.


REFERENCES

  1. Valdivia G, Bastías G, Márquez P. Magnitud de la Enfermedad Crónica en Chile. Boletín de la Esc Medicina. 1994; 23(1):35-40.Disponible en: http://escuela.med.puc.cl/paginas/publicaciones/boletin/html/salud_publica/1_9.html

  2. Jasperson KW, Vu TM, Schwab AL, Neklason DW, Rodriguez-Bigas MA, Burt RW,et al. Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. Fam Cancer. 2010 Jun;9(2):99-107.Available from: http://link.springer.com/article/10.1007%2Fs10689-009-9290-4

  3. Castells A, Piqué JM. Tumores intestinales. En: Farreras V, Rozman C, Medicina interna 14ª ed. Madrid: Harcourt; 2010p.261-272.

  4. Vasen HF, Möslein G, Alonso A, Bernstein I, Bertario L, Blanco I,et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007 Jun; 44(6):353-62.Available from: http://jmg.bmj.com/content/44/6/353.long

  5. Steinke V, Engel C, Büttner R, Schackert HK, Schmiegel WH, Propping P. Hereditary Nonpolyposis Colorectal Cancer (HNPCC)/Lynch Syndrome. Dtsch Arztebl Int. 2013 Jan; 110(3):32-8.Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566622/

  6. Volgestein B, Kinzler KW. The Genetic Basis of Human Cancer. NewYork: McGraw-Hill; 1998.

  7. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 jutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 2001 Oct 15; 19(20):4074-80. Available from: http://jco.ascopubs.org/content/19/20/4074.long

  8. Moreira L, Balaguer F, Lindor N, de la Chapelle A , Hampel H, Aaltonen LA, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012 Oct 17; 308(15):1555-65.Available from: http://jama.jamanetwork.com/article.aspx?articleid=1383232

  9. Park YJ, Shin KH, Park JG. Risk of Gastric Cancer in Hereditary Nonpolyposis Colorectal Cancer in Korea . Clin Cancer Res. 2000 Aug; 6(8):2994-8. Available from: http://clincancerres.aacrjournals.org/content/6/8/2994.long

  10. Suehiro Y, Hinoda Y. Genetic and epigenetic changes in colorectal cancer and genetic testing for personalized medicine. Rinsho Byori. 2012 Oct; 60(10):976-81 Available from: http://preview.ncbi.nlm.nih.gov/pubmed/23323463

  11. Reeves SG, Meldrum C, Groombridge C, Spigelman AD, Suchy J, Kurzawski G, et al. MTHFR 677 C>T and 1298 A>C polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. Eur J Hum Genet. 2009 May; 17(5):629-35. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2986255/

  12. Reeves SG, Rich D, Meldrum CJ, Colyvas K, Kurzawski G, Suchy J, et al. IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer. Int J Cancer. 2008 Sep 15; 123(6):1339-43. Available from: http://onlinelibrary.wiley.com/doi/10.1002/ijc.23668/abstract

  13. Russo A, Sala P, Alberici P, Gazzoli I, Radice P, Montefusco C, et al. Prognostic relevance of MLH1 and MSH2 mutations in hereditary non-polyposis colorectal cancer patients. Tumori. 2009 Nov-Dec; 95(6):731-8. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/?term=Russo+A%2C+Sala+P%2C+Alberici+P%2C+Gazzoli+I%2C+Radice+P%2C+Montefusco+C%2C+et+al.+Prognostic+relevance+of+MLH1+and+MSH2+mutations+in+hereditary+non-polyposis+colorectal+cancer+patients.+Tumori.+2009+Nov-Dec%3B95%286%29%3A731-8




2020     |     www.medigraphic.com